文献速递产科母胎医学

体外受精与妊娠期高血压疾病风险:与治疗参数的关联

In vitro fertilization and risk for hypertensive disorders of pregnancy: associations with treatment parameters.
PubMed 文献 · Am J Obstet Gynecol · 2019-10-17

研究纳入美国8个州2004-2013年体外受精后活产的83582例及1382311例自然受孕单胎,按卵源和胚胎状态分层分析妊娠期高血压疾病风险。相比自然受孕,自体卵母细胞-新鲜胚胎移植未见风险增加(aOR 1.04,95%CI 0.99-1.08);自体卵母细胞-冻融胚胎、供卵-新鲜胚胎和供卵-冻融胚胎风险均升高。

要点

  • 自体卵母细胞-新鲜胚胎移植者妊娠期高血压疾病风险与自然受孕相比无显著增加。
  • 自体卵母细胞-冻融胚胎、供卵-新鲜胚胎和供卵-冻融胚胎移植者风险均升高。
  • 排除孕前糖尿病或慢性高血压及调整BMI和不孕诊断后结果无实质改变。

核心结论

  • 体外受精治疗中,冻融胚胎移植(无论自体或供卵)和新鲜供卵胚胎移植者妊娠期高血压疾病风险升高,而自体卵母细胞-新鲜胚胎移植周期未见风险增加。

研究设计与样本

  • 研究将美国8个州2004-2013年体外受精后活产的妇女与其婴儿出生证明链接,并选取10:1比例的非体外受精分娩作为对照。
  • 出生证明上标注不孕治疗者被归类为亚 fertile 并排除,其余归类为生育力正常;体外受精妊娠按卵源(自体 vs 供卵)和胚胎状态(新鲜 vs 冻融)分类。
  • 分析限于单胎,体外受精妊娠限于使用伴侣精子;研究人群共1,465,893例妊娠(生育力正常妇女1,382,311例,体外受精治疗妇女83,582例)。

主要发现

  • 与生育力正常妇女相比,自体卵母细胞-新鲜胚胎移植的体外受精妇女妊娠期高血压疾病风险未增加(aOR 1.04;95%CI 0.99-1.08)。
  • 在体外受精组内,以自体卵母细胞-新鲜胚胎为参照,自体卵母细胞-冻融胚胎(aOR 1.30;95%CI 1.20-1.40)、供卵-新鲜胚胎(aOR 1.92;95%CI 1.71-2.15)和供卵-冻融胚胎(aOR 1.70;95%CI 1.47-1.96)的妊娠期高血压疾病风险均升高。
  • 排除孕前糖尿病或慢性高血压以及调整体重指数和不孕诊断后,结果无实质改变。
  • 按<34周(早发型)和≥34周(晚发型)分层,仅供卵-新鲜胚胎组早发型妊娠期高血压疾病风险升高;与自体卵母细胞-新鲜胚胎相比,其他所有卵源-胚胎状态组的晚发型风险均升高。

关键数值与推荐

  • 以生育力正常妇女为参照,自体卵母细胞-新鲜胚胎移植组妊娠期高血压疾病aOR 1.04(95%CI 0.99-1.08)。
  • 以自体卵母细胞-新鲜胚胎为参照,自体卵母细胞-冻融胚胎组aOR 1.30(95%CI 1.20-1.40),供卵-新鲜胚胎组aOR 1.92(95%CI 1.71-2.15),供卵-冻融胚胎组aOR 1.70(95%CI 1.47-1.96)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although in vitro fertilization has been associated with an increased risk for hypertensive disorders of pregnancy, the association of risk with in vitro fertilization treatment parameters is unclear. OBJECTIVE: To evaluate risk for hypertensive disorders of pregnancy by maternal fertility status and in vitro fertilization treatment parameters. MATERIALS AND METHODS: Women in 8 states who underwent in vitro fertilization resulting in a live birth during 2004-2013 were linked to their infant's birth certificates. A 10:1 sample of births from non-in vitro fertilization deliveries were selected for comparison. Those with an indication of infertility treatment on the birth certificate were categorized as subfertile and omitted from the study population; all others were categorized as fertile. The in vitro fertilization pregnancies were additionally categorized by oocyte source (autologous versus donor) and embryo state (fresh versus thawed). Both the fertile and in vitro fertilization births were limited to singletons only, and the in vitro fertilization pregnancies were limited to those using partner sperm. Hypertensive disorders of pregnancy (including gestational hypertension and preeclampsia) were identified from the birth certificate, modeled using logistic regression, and reported as adjusted odds ratios and 95% confidence intervals. For analyses of in vitro fertilization pregnancies from autologous oocytes-fresh embryos, the reference group was fertile women (subgroup analysis 1). For analyses within the in vitro fertilization group, the reference group was autologous oocytes-fresh embryos (subgroup analysis 2). RESULTS: The study population included 1,465,893 pregnancies (1,382,311 births to fertile women and 83,582 births to in vitro fertilization-treated women). Compared to fertile women, in vitro fertilization-treated women with autologous-fresh cycles were not at increased risk for hypertensive disorders of pregnancy (adjusted odds ratio, 1.04; 95% confidence interval, 0.99, 1.08). Among in vitro fertilization births (subgroup analysis 2), the risk for hypertensive disorders of pregnancy was increased for the autologous-thawed (adjusted odds ratio, 1.30; 95% confidence interval, 1.20, 1.40); donor-fresh (adjusted oddds ratio, 1.92; 95% confidence interval, 1.71, 2.15); and donor-thawed (adjusted odds ratio, 1.70; 95% confidence interval, 1.47, 1.96) groups. Excluding women with pregestational diabetes or chronic hypertension as well as adjusting for body mass index and infertility diagnoses did not substantially change the results. When stratified by <34 weeks (early-onset hypertensive disorders of pregnancy) versus ≥34 weeks (late-onset hypertensive disorders of pregnancy), only the donor-fresh group had an increased risk of early-onset hypertensive disorders of pregnancy, but the risks for all other oocyte source-embryo state groups compared to autologous-fresh were increased for late-onset hypertensive disorders of pregnancy. CONCLUSION: The risk for hypertensive disorders of pregnancy is increased for in vitro fertilization-treated women in pregnancies conceived via frozen embryo transfer (with both autologous or donor oocyte) and fresh donor oocyte embryo transfer. No increase in risk was seen with autologous oocyte-fresh embryo transfers in vitro fertilization cycles. Excluding women with pregestational diabetes or chronic hypertension as well as adjusting for body mass index and infertility diagnoses did not substantially change the results.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Luke B, Brown MB, Eisenberg ML, et al. In vitro fertilization and risk for hypertensive disorders of pregnancy: associations with treatment parameters. Am J Obstet Gynecol. 2019. PMID: 31629726. doi:10.1016/j.ajog.2019.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。